IL-10 and IL-12 (P70) Levels Predict the Risk of Covid-19 Progression in Hypertensive Patients: Insights From the BRACE-CORONA Trial

Background: Cardiovascular comorbidities such as hypertension and inflammatory response dysregulation are associated with worse COVID-19 prognoses. Different cytokines have been proposed to play vital pathophysiological roles in COVID-19 progression, but appropriate prognostic biomarkers remain lack...

Full description

Saved in:

Bibliographic Details
Published in:	Frontiers in cardiovascular medicine Vol. 8; p. 702507
Main Authors:	Moll-Bernardes, Renata, de Sousa, Andrea Silvestre, Macedo, Ariane V. S., Lopes, Renato D., Vera, Narendra, Maia, Luciana C. R., Feldman, André, Arruda, Guilherme D. A. S., Castro, Mauro J. C., Pimentel-Coelho, Pedro M., de Albuquerque, Denílson C., de Paula, Thiago Ceccatto, Furquim, Thyago A. B., Loures, Vitor A., Giusti, Karla G. D., de Oliveira, Nathália M., De Luca, Fábio A., Kotsugai, Marisol D. M., Domiciano, Rafael A. M., Santos, Mayara Fraga, de Souza, Olga Ferreira, Bozza, Fernando A., Luiz, Ronir Raggio, Medei, Emiliano
Format:	Journal Article
Language:	English
Published:	Frontiers Media S.A 27-07-2021
Subjects:	biomarker Cardiovascular Medicine COVID-19 cytokine hypertension inflammation prognosis
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Background: Cardiovascular comorbidities such as hypertension and inflammatory response dysregulation are associated with worse COVID-19 prognoses. Different cytokines have been proposed to play vital pathophysiological roles in COVID-19 progression, but appropriate prognostic biomarkers remain lacking. We hypothesized that the combination of immunological and clinical variables at admission could predict the clinical progression of COVID-19 in hypertensive patients. Methods: The levels of biomarkers, including C-reactive protein, lymphocytes, monocytes, and a panel of 29 cytokines, were measured in blood samples from 167 hypertensive patients included in the BRACE-CORONA trial. The primary outcome was the highest score during hospitalization on the modified WHO Ordinal Scale for Clinical Improvement. The probability of progression to severe disease was estimated using a logistic regression model that included clinical variables and biomarkers associated significantly with the primary outcome. Results: During hospitalization, 13 (7.8%) patients showed progression to more severe forms of COVID-19, including three deaths. Obesity, diabetes, oxygen saturation, lung involvement on computed tomography examination, the C-reactive protein level, levels of 15 cytokines, and lymphopenia on admission were associated with progression to severe COVID-19. Elevated levels of interleukin-10 and interleukin-12 (p70) combined with two or three of the abovementioned clinical comorbidities were associated strongly with progression to severe COVID-19. The risk of progression to severe disease reached 97.5% in the presence of the five variables included in our model. Conclusions: This study demonstrated that interleukin-10 and interleukin-12 (p70) levels, in combination with clinical variables, at hospital admission are key biomarkers associated with an increased risk of disease progression in hypertensive patients with COVID-19.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: Masanori Aikawa, Brigham and Women's Hospital and Harvard Medical School, United States Reviewed by: Angelo Silverio, University of Salerno, Italy; Valeria Visco, University of Salerno, Italy These authors have contributed equally to this work and share last authorship This article was submitted to Hypertension, a section of the journal Frontiers in Cardiovascular Medicine
ISSN:	2297-055X 2297-055X
DOI:	10.3389/fcvm.2021.702507